Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CTLA-4 polymorphisms are associated with treatment outcomes of patients with multiple myeloma receiving bortezomib-based regimens.

Annals of hematology - 1 Mar 2018

Qin Xiao-Ying, Lu Jin, Li Guo-Xuan, Wen Lei, Liu Yang, Xu Lan-Ping, Chang Ying-Jun, Liu Kai-Yan, Jiang Zheng-Fan, Huang Xiao-Jun

Abstract excerpt

Single-nucleotide polymorphisms (SNPs) of cytotoxic T lymphocyte antigen-4 (CTLA-4) are important risk factors associated with autoimmune diseases and malignancies. This study explored the association of CTLA-4SNPs with the development of myeloma and evaluated the outcome of patients receiving bortezomib-based regimens in relation to CTLA-4SNPs. Peripheral blood samples from 86 patients with multiple myeloma (MM)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Bortezomib

Share to Case-Control Studies

Share to CTLA-4 Antigen

Share to Multiple Myeloma

Share to Treatment Outcome

Source

Identifiers

PMID: 29264740
DOI: 10.1007/s00277-017-3203-7

Genes

CTLA4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CTLA-4 polymorphisms are associated with treatment outcomes of patients with multiple myeloma receiving bortezomib-based regimens.PMID 29264740Read ↗

Genetic variants of CTLA4 are associated with clinical outcome of patients with multiple myeloma.Semantic proximity Read ↗

TLR4/TIRAP polymorphisms are associated with progression and survival of patients with symptomatic myeloma.Semantic proximity Read ↗

Polymorphisms of nuclear factor-κB family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens.Semantic proximity Read ↗

Impact of Genetic Polymorphisms on Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma: A Systematic Review and Bioinformatics Analysis.Semantic proximity Read ↗

Polymorphism of IL-10 receptor β affects the prognosis of multiple myeloma patients treated with thalidomide and/or bortezomib.Semantic proximity Read ↗

Variations in suppressor molecule ctla-4 gene are related to susceptibility to multiple myeloma in a polish population.Semantic proximity Read ↗

Association between BCL2 interacting protein 3 like (BNIP3L) genetic polymorphisms and the risk of multiple myeloma in China.Semantic proximity Read ↗

Impact of Genetic Polymorphisms in NF-ĸB2 and TRAF3 Genes on Response to Bortezomib-Based Therapy in Multiple Myeloma Patients.Semantic proximity Read ↗

Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array.Semantic proximity Read ↗

Polymorphisms within genes encoding Ikaros family proteins IKZF1 and IKZF3 in multiple myeloma patients treated with thalidomide.Semantic proximity Read ↗

Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients.Semantic proximity Read ↗

Genetic variations in multiple myeloma II: association with effect of treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.